- Home
- DHF vs INBX Comparison
DHF vs INBX Comparison
Compare DHF & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHF
- INBX
- Stock Information
- Founded
- DHF 1998
- INBX 2010
- Country
- DHF United States
- INBX United States
- Employees
- DHF N/A
- INBX 161
- Industry
- DHF Finance Companies
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- DHF Finance
- INBX Health Care
- Exchange
- DHF Nasdaq
- INBX Nasdaq
- Market Cap
- DHF 174.6M
- INBX 168.1M
- IPO Year
- DHF N/A
- INBX 2020
- Fundamental
- Price
- DHF $2.40
- INBX $11.47
- Analyst Decision
- DHF
- INBX Hold
- Analyst Count
- DHF 0
- INBX 1
- Target Price
- DHF N/A
- INBX N/A
- AVG Volume (30 Days)
- DHF 451.1K
- INBX 144.3K
- Earning Date
- DHF 01-01-0001
- INBX 05-08-2025
- Dividend Yield
- DHF 7.65%
- INBX 7.40%
- EPS Growth
- DHF N/A
- INBX N/A
- EPS
- DHF N/A
- INBX 112.62
- Revenue
- DHF N/A
- INBX $200,000.00
- Revenue This Year
- DHF N/A
- INBX N/A
- Revenue Next Year
- DHF N/A
- INBX N/A
- P/E Ratio
- DHF N/A
- INBX $0.10
- Revenue Growth
- DHF N/A
- INBX N/A
- 52 Week Low
- DHF $2.06
- INBX $10.80
- 52 Week High
- DHF $2.39
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- DHF 42.17
- INBX 34.68
- Support Level
- DHF $2.25
- INBX $10.81
- Resistance Level
- DHF $2.43
- INBX $12.06
- Average True Range (ATR)
- DHF 0.07
- INBX 1.00
- MACD
- DHF 0.00
- INBX -0.19
- Stochastic Oscillator
- DHF 54.55
- INBX 18.52
About DHF BNY Mellon High Yield Strategies Fund
BNY Mellon High Yield Strategies Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income and its secondary objective is capital appreciation. It invests predominantly in fixed-income securities of below-investment-grade credit quality.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.